( June 1, 2026, 23:00 GMT | Official Statement) -- MLex Summary: Plaintiffs suing Sandoz AG, Novartis, and other generic drugmakers opposed Sandoz AG's motion for reconsideration of an order denying dismissal of plaintiffs' US antitrust claims, saying that the drugmaker's arguments "[put] a new coat of paint on the same group-pleading and sufficiency-of-the-evidence arguments that filled its motion-to-dismiss papers, but ultimately there is nothing in Sandoz AG’s motion that compels a different result." The court's opinion did not announce a new legal standard, did not contain factual mistakes, and relied on established US Court of Appeals for the Third Circuit case law, the plaintiffs said in a filing to the Eastern District of Pennsylvania.See attached document: ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.